Table 3.
Human immunodeficiency virus prevalence among high risk human immunodeficiency virus parenteral-transmission population groups in the Middle East and North Africa (other than people who inject drugs)
| Country | Population | Seroprevalence (%) | Ref. |
| Bahrain | Children with hereditary hemolytic anemia | 1.6 | [257] |
| Egypt | Blood or blood products recipients | 4.8 | [380] |
| Thalassemia patients | 0 | [381] | |
| Children with hemophilia | 0 | [382] | |
| Iran | Thalassemia patients | 0 | [44,113,160,168,277,284,288-291,383] |
| Hemophilia patients | 0-2.3 | [161,277,281-284,287] | |
| Jordan | Multi-transfused patients | 0 | [304] |
| Lebanon | Multi-transfused patients | 0 | [384] |
| Morocco | Hemodialysis patients | 0 | [316] |
| Pakistan | Multi-transfused patients | 0.98 | [385] |
| Hemodialysis patients | 0.98 | [277] | |
| Qatar | Children with thalassemia | 38.5 | [386] |
| Saudi Arabia | Multi-transfused, thalassemia and sickle cell disease patients | 1.3 | [387] |
| Children undergoing cancer therapy | 0 | [70] | |
| Hemodialysis patients | 0 | [388] | |
| Tunisia | Hemodialysis patients | 0 | [359] |
| Hemophiliacs | 8.6 | [365] |
Results shown are not of an exhaustive and systematic literature review.